Characterization of antimicrobial resistance in hospitals and contributions of ASP and AC actions, Bogotá 2019 to 2023
DOI:
https://doi.org/10.56085/bed.600Keywords:
antimicrobial resistance, hospital, antibiotics, optimization, Enterobacterales, carbapenemsAbstract
Antimicrobial resistance (AMR) is a serious global threat to human health, especially in hospital settings, where the high and sometimes inappropriate use of antibiotics accelerates the progression of AMR. Several studies have evaluated the impact of AMR on incidence rates, mortality, length of hospital stay, and health care costs for specific combinations of pathogens and drugs.
A marked increase in carbapenem resistance, particularly Klebsiella pneumoniae, was observed in the Capital District of Bogotá between 2021 and 2023, both in intensive care units (ICUs) and in non-ICU services. In 2023, the co-production of KPC-NDM-SHV reached 40%, while that of KPC-NDM was 18.6%.
According to the literature, risk factors for acquiring carbapenemase-producing microorganisms include the presence of comorbidities, prolonged hospital stays, the use of invasive devices and supportive therapies, and prolonged administration of broad-spectrum antibiotics. This situation was exacerbated by the COVID-19 pandemic, which placed significant pressure on health care services, especially in 2021.
Author Biographies
Luz Amparo Sastoque Diaz, Secretaría Distrital de Salud
Subdirección Vigilancia en Salud Pública.
Paola Carolina Correal Tovar, Secretaría Distrital de Salud
Subdirección Vigilancia en Salud Pública.
Yaniz Rocio Hernández Gonzalez, Secretaría Distrital de Salud
Subdirección Vigilancia en Salud Pública.
References
World Health Organization. Plan de acción mundial sobre la resistencia a los antimicrobianos. Ginebra: Organización Mundial de la Salud; 2016. ISBN: 978 92 4 350976 1
Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. [Internet]. 2022; 399(10325): 629-55. Disponible en: https://doi.org/10.1016/S0140-6736(21)02724-0
European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe. [Internet]. 2022. Disponible en: https://iris.who.int/handle/10665/351141
Centers for Disease Control and Prevention. COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022. [Internet]. Atlanta, Georgia; 2022. Disponible en: https://stacks.cdc.gov/view/cdc/117915
Instituto Nacional de Salud. Vigilancia por laboratorio de resistencia antimicrobiana en infecciones asociadas a la atención en salud (IAAS). Colombia, años 2012 a 2020. Bogotá: Instituto Nacional de Salud; 2021.
Secretaría Distrital de Salud. Boletín distrital resistencia bacteriana. Colombia, 2017-2021. Bogotá: Secretaría Distrital de Salud; 2021. https://doi.org/10.56085/01238590.215
Instituto Nacional de Salud. Informe técnico del evento de vigilancia por Whonet de resistencia antimicrobiana en el ámbito hospitalario. [Internet]. Colombia, 2022 Bogotá: Instituto Nacional de Salud; 2022. Disponible en: https://www.ins.gov.co/BibliotecaDigital/vigilancia-por-whonet-de-resistencia-antimicrobiana-en-el-ambito-hospitalario-colombia-2022.pdf, https://doi.org/10.33610/858878jgmyhe
World Health Organization. Global antimicrobial resistance and use surveillance system (GLASS) report: 2022. Geneva: World Health Organization; 2022. Disponible en: https://www.who.int/publications/i/item/9789240062702
Centros para el Control y la Prevención de Enfermedades. COVID-19: impacto en la resistencia a los antimicrobianos en los EE. UU., Informe especial del 2022 [Internet]. Disponible en: https://www.cdc.gov/antimicrobial-resistance/media/pdfs/covid19-impact-report-508.pdf
Centers for Disease Control and Prevention. Carbapenem-Resistant-Enterobacterales. [Internet]. Disponible en: https://arpsp.cdc.gov/profile/arln/cre?tabsection-163=0&hidden=
Robertson J, Trost M, Wong G, Jaki T. Changes in hospital antibiotic consumption during the COVID-19 pandemic. Antimicrob Resist Infect Control. [Internet]. 2021; 10(1): 87. Disponible en: https://doi.org/10.1186/s13756-021-00987-6
González-Martín C, del Mar TM, Galán-Sánchez F, Sánchez-Hernández N, Cantón R. Impacto de la pandemia de COVID-19 en el consumo de antibióticos y la resistencia antimicrobiana en España. Rev Esp Quimioter. [Internet]. 2023; 36(1): 55-61. Disponible en: https://doi.org/10.37201/re.q.2023.2301
Klein EY, Van Boeckel TP, Martinez EM, Pant S, Laxminarayan R. Global trends in antibiotic consumption and resistance during the COVID-19 pandemic. J Glob Antimicrob Resist. [Internet]. 2023; 32: 102-10. Disponible en: https://doi.org/10.1016/j.jgar.2022.12.003
Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: A cross-national database study. Lancet Infect Dis. [Internet]. 2022; 10(11): 1182-90. Disponible en: https://doi.org/10.1016/S1473-3099(10)70270-6
Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M. Relationship between antibiotic consumption and antibiotic resistance in Escherichia coli: a systematic review. Antimicrob Resist Infect Control. [Internet]. 2020; 3(1): 1-25. Disponible en: https://doi.org/10.1186/s13756-014-0021-0
